RxDoctor Payments Data

Mladen Vidovich, MD

Cardiovascular Disease · Chicago, ILNPI 1952350621

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 38.0% of the total. Reporting peaked in 2022 at $3,208 and has fallen 91.6% since, to $269 in 2025.

$12,014in general payments, 2019–2025

Across 92 payments — averaging $130.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$3K
  • GE HealthCare$855
  • Inari Medical, Inc.$751
  • Cordis US CORP.$517
  • Biotronik Inc.$412
  • plus $2K from 16 others
$152,471in research payments, 2019–2025

Across 68 payments — averaging $2242.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$132K
  • Janssen Research & Development, LLC$20K

What the payments were for

  • Consulting fees$6,79357%
  • Travel & lodging$160%
  • Food & beverage$5,14443%
  • Education$621%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,014 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$52,154
Medicare patients
788
Services billed
1,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan37$61,943
JardianceEmpagliflozin25$41,026
EliquisApixaban27$35,825
OzempicSemaglutide12$16,754
Praluent PenAlirocumab34$16,318
FarxigaDapagliflozin Propanediol11$16,034
RybelsusSemaglutide11$14,660
Rosuvastatin Calcium44$1,538
Atorvastatin Calcium114$1,072
Candesartan Cilexetil12$1,002
Metoprolol Succinate50$948
Ezetimibe29$630
Carvedilol70$587
Losartan Potassium26$294
Amlodipine Besylate41$202

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →